Event Highlights
Marriott Marquis San Diego,
Live In-Person Event: December 15 - 18, 2024
It all comes together in San Diego with 5 Days of Content, 15 Tracks, 13 Scientific Briefings and 3 Pre-conference Workshops
What Will You Learn?
Learn how to engineer antibody therapeutics with improved drug-like properties to better combat a variety of diseases and to gain a competitive advantage over existing therapeutics already on the market at:
- Track 1: Immunogenicity
- Track 2: Antibody Developability
Find Novel Targets and Discovery Strategies to Develop Antibody, Antibody-Like and Protein Therapeutics at:
- Pre-conference workshop: Next-Generation Sequencing for Antibody Library Analysis and Monocloncal Discovery and Engineering – Sunday
- Novel Methods to Interrogate Receptors as Targets – Monday
- Libraries, Display, Selection and Screening – Wednesday
Decide which therapeutic modality (antibody therapeutic, bispecific, fusion protein, antibody alternative, ADC, CAR-T etc.) will give you the greatest chance of success in developing new therapeutics at:
- CAR-T Cell Recruitment in Solid Tumors – Tuesday
- Preclinical and Clinical Antibodies in Development – Friday
- Clinical Stories: Antibodies in Development - Friday
Learn how to manipulate the immune system to develop novel therapeutics at:
- Pre-conference workshop: Immuno-engineering: Bridging the Immune System and Antibody Therapeutics – Sunday
- Meeting Challenges for Antibody Therapies in the Tumor Microenvironment - Tuesday
- Clonal Expansion of Lymphocytes in Immune Repertoire - Wednesday
Find new disease applications of antibody therapeutics beyond cancer at:
- Novel Indications for Therapeutic Antibodies - Tuesday
- Engineering & Application of Therapeutic Antibodies for Neurodegenerative Diseases – Tuesday
- Vaccines and Antibodies in Infectious Diseases – Wednesday
Discover New Frontiers in Novel Therapeutic Development at:
- Microbiome Therapeutics – Wednesday
- Innovating Antibody Therapeutics - Thursday
NOVEL METHODS TO INTERROGATE RECEPTORS AS TARGETS
Chairperson: Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland
Clinically Important Receptors and Techniques for Interrogating Them
Ira Mellman, Ph.D., Vice President, Cancer Immunology, Genentech
More Than Blocking Ligands: Designing Therapeutic Proteins to Surface Receptors
Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland
Decoding Ligand Receptor Interactions
Bernd Wollscheid, Ph.D., Professor, Chemical & Systems Biology, Institute of Molecular Systems Biology and Department of Health Sciences and Technology (D-HEST), ETH Zurich, Switzerland
Laura P.W. Ranum, Ph.D., Director, Center for NeuroGenetics, Kitzman Family Professor of Molecular Genetics and Microbiology, College of Medicine, University of Florida
Pathology From the Molecular Scale On Up
Garry P. Nolan, Ph.D., Rachford and Carlota A. Harris Professor, Department of Microbiology & Immunology, Baxter Laboratory for Stem Cell Biology, Stanford University School of Medicine
Emerging Approaches to Modulate Receptor Function in Stem Cells
Rami Hannoush, Ph.D., Principal Scientist & Group Leader, Early Discovery Biochemistry, Genentech
xPloration™: A Platform Enabling High-throughput Functional Screening of Antibody Libraries
Jennifer Cochran, Ph.D., Associate Professor, Bioengineering & Chemical Engineering, Stanford University and Co-Founder and Chairman, xCella Biosciences
NOVEL ENGINEERING STRATEGIES TO ENHANCE ANTIBODY FUNCTIONS
Session Chair: Paul J. Carter, Ph.D., Senior Director and Staff Scientist, Antibody Engineering, Genentech, Inc.
From Format to Function - Transformative Antibody Therapeutics
Martin Steegmaier, Ph.D., Head of Discovery, Large Molecule Research, Roche pRED, Roche Innovation Center Munich, Germany
Agonizing the TNFR Superfamily for Cancer Immunotherapy
Greg Lazar, Ph.D., Director and Senior Scientist, Antibody Engineering, Genentech
Adapted Fc-glycan Changes for Enhanced ADCC and/or CDC
Gestur Vidarsson, Ph.D., Head of Immunoglobulin Research/PI, Experimental Immunohematology, Sanquin Research, The Netherlands
BIOLOGICAL IMPACT OF FC RECEPTOR ENGAGEMENT
Session Co-Chairs:
- Trudi Veldman Ph.D., Senior Director Biologics, AbbVie Bioresearch Center
- Chung-Ming Hsieh, Executive Director, Biologics Discovery Boston, Merck Research Laboratories
SKY59: Novel Recycling Antibody against C5 with Improved Pharmacokinetics for the Treatment of Complement-mediated Diseases
Kenta Haraya, Ph.D., Scientist, Research Division, Biologics Discovery, Chugai Pharmaceutical Co Ltd., Japan
Novel Effector Function Attenuating Mutations That Maintain Antibody Stability and Reduce Toxicity
James A. Ernst, Ph.D., Senior Scientist & Group Leader, Department of Protein Sciences, Genentech
Antibody Optimization for Treg Depletion in Cancer Therapy
Frederick Arce Vargas, M.D. Ph.D., Research Associate, University College London Cancer Institute, United Kingdom
Selective FcγR Engagement by Agonistic Anti-CD40 Abs
Rony Dahan, Ph.D., Principal Investigator, Department of Immunology, Weizmann Institute of Science, Israel
Potent Antitumor Activity of IL2-Fc Requires Fc-mediated Depletion of Tregs
Daniel Christ, Ph.D., Associate Professor and Head Antibody Therapeutics, Director Centre for Targeted Therapy, Immunology Program, Garvan Institute of Medical Research
ROLE OF POST-TRANSLATIONAL MODIFICATION IN ANTIBODY FUNCTION
Session Co-Chairs:
- Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbial Science, The Scripps Research Institute
- Paul Parren, Ph.D., Senior Vice President and Scientific Director, Genmab, The Netherlands
Fc Fucosylation and Sialylation and Antibody Effector Function
Jeffrey Ravetch, Ph.D., Professor, Rockefeller University
Sulfation of Broadly Neutralizing HIV Antibodies
Raiees Andrabi, Research Associate, The Burton Lab,The Scripps Research InstitutePRELIMINARY AGENDA
Integrative Mass Spectrometric Structural Analysis of Glycoprotein Therapeutics and Its Usage to Evaluate and Score Biosimilarity
Albert J. R. Heck, Ph.D., Professor and Science Faculty, Utrecht University, The Netherlands
Post-translational Modification of Antibodies in Rheumatoid Arthritis
Leendert A. Trouw Ph.D., Assistant, Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden,The Netherlands
Regulation of Autoantibody Activity by the IL-23–TH17 Axis and its Impact on Autoimmune Disease
Gerhard Krönke, M.D., Professor of Translational Immunology, Department of Internal Medicine 3, Institute of Rheumatology and Immunology, University of Erlangen-Nuremberg Germany
IMMUNO-ONCOLOGY: CHECKPOINTS
Session Chair:
- James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development
SIMPLE Antibody™ Platform Generates Unique Species Cross-reactive Antibodies against Immune Checkpoints
Erik Hofman, Ph.D., Senior Scientist, Research Department, Argenx, Belgium
Immuno-oncology and Prostate Cancer
Xin Lu, Professor M.D., University of Notre Dame
A Novel Cytokine Receptor Agonistic Antibody by Design
Cheng-I Wang, Ph.D., Senior Principal Investigator, Singapore Immunology Network, Biomedical Sciences Institutes, ASTAR, Singapore
Boosting Cancer Immunotherapy with Combined Immunomodulatory Drugs
Mickey Hu, Ph.D., Scientist, Panorama Institute of Molecular Medicine
Cow Ultralong CDR3 Antibodies Targeting Exhausted T-cells
Vaughn Smider M.D., Ph.D., Associate Professor, Molecular Medicine, The Scripps Research Institute
ANTIBODY BASED INNOVATIONS IN THE TUMOR MICROENVIRONMENT
Session Co-Chairs:
- Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom
- Janine Schuurman, Ph.D., Vice President, Research, Genmab, The Netherlands
Protia – Bispecific T-Cell Engagers Designed for Local Activation in the Tumor Environment
Volker Schellenberger, Ph.D., CEO and President, Amunix
Immuno-Viral Therapy for Solid Tumors
Maria Navarro, M.D., Project & Operations Manager, Icell Kealex Therapeutics
Costimulation of Immune Cells in the Tumor Microenvironment via Bispecific DART® and TRIDENT™ Molecules
Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics
Harnessing Fc Gamma Receptor Biology to Optimize Antibodies Targeting TNFR Superfamily Members
Nick Wilson, Ph.D., Executive Director of Immuno-modulatory Drug Discovery, Agenus
mRNA Vaccination and Combination Therapy with Immunomodulating Antibodies
Sebastian Kreiter, Head, Tron/BioNTech, Germany
An Update on the Darzalex Story
Kate Sasser, Ph.D., Vice President, Head of Oncology Translational Research, Janssen
OVERCOMING DELIVERY CHALLENGES INCLUDING BRAIN AND INTRACELLULAR TARGETS
Session Co-Chairs:
- Paul J. Carter, Ph.D., Senior Director and Staff Scientist, Antibody Engineering, Genentech, Inc.
- Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland
Bacterial Secretion Systems
Thomas Marlovits, Professor, Institute of Molecular Pathology, Austria
Nanobodies as Inhaled Biotherapeutics for Lung Diseases, with ALX-0171 (anti-RSV) as a Case Study
Antonin De Fourgerolles, Ph.D., Chief Scientific Officer, Ablynx, Belgium
Bispecific Antibodies Targeting Transfer in Receptor or CD98 to Facilitate Delivery Across the Blood Brain Barrier
Jasi Atwal, Scientist, Genentech
Artificial Immunotoxins
Ernst Wagner, Ph.D., Chair, Pharmaceutical Biotechnology, Center for System-based Drug Research, Center for Nanoscience, Ludwig Maximilians University, Germany
ANTIBODY-DRUG CONJUGATES & FUSION PROTEINS
Session Chair:
- Gregory Adams, Ph.D., Chief Scientific Officer, Eleven Biotherapeutics
Redox Selenium ADCs Improve Cancer Cell Monoclonal Antibody Cytotoxicity
Julian Spallholz, Ph.D., Professor, Nutritional Sciences,Texas Tech University
Antibody-Drug Conjugates for Treating Steroid-Resistant Malignancies and Autoimmune Diseases
Masahiro Yasunaga, M.D., Ph.D., Unit Leader, Developmental Therapeutics,National Cancer Center, Japan
Targeting Tumors and Their Vasculature with Antibody-Drug Conjugates
Dimiter Dimitrov, Ph.D., Senior Investigator, CCR, Cancer and Inflammation Program, NCI-Frederick, NIH
Novel Calicheamicin Antibody-Drug Conjugates
Julia Gavrilyuk, Ph.D., Principal Scientist, Discovery Chemistry, Abbvie Stemcentrx
NOVEL ANTIBODY DISPLAY, SELECTION AND SCREENING
Session Chair:
Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica
Using Next Generation Sequencing in Antibody Libraries
Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica
Quantitative Proteomics
Jim Wells, Professor, UCSF
Engineering Developable Antibodies
Peter Tessier, Professor, Rensselaer Polytechnic Institute
Programming Antibodies and Antigens using Deep Sequencing-Enabled Protein Engineering
Tim Whitehead, Ph.D., Associate Professor, Chemical Engineering and Materials Science, Michigan State University
Advances in Yeast Display Selections for Membrane Targets
Benjamin Hackel, Ph.D., Assistant Professor, Chemical Engineering and Materials Science, University of Minnesota
Functional Interrogation and Mining of Natively Paired Heavy:Light Human Antibody Repertoires
Department of Pharmaceutical Chemistry, The University of Kansas
ROLE OF THE T-CELL REPERTOIRE IN CANCER, INFECTIOUS DISEASES AND AUTOIMMUNITY
Session Chair: Jamie K. Scott, M.D., Ph.D., Professor and Canada Research Chair in Molecular Immunity, Department of Molecular Biology & Biochemistry and Faculty of Health Sciences, Simon Fraser University, Canada
Genetic Variation in MHC Proteins is Associated with T-cell Receptor Expression Biases
Eilon Sharon, Ph.D., Postdoctoral Fellow, Howard Hughes Medical Institute, Stanford University
CD8 T-cell Repertoire Dynamics and Their Association with HCV Clearance
Naglaa H. Shoukry, Ph.D., Associate Professor, Department of Medicine, University of Montreal, Canada
CD39 and CD103 Identify Tumor-reactive CD8 T-cells in Human Solid Tumors
Thomas Duhen, Ph.D., Senior Research Scientist, AgonOx
ANTI-TUMOR ANTIGEN ANTIBODIES IN CANCER IMMUNOTHERAPY
Session Chair: K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
Tumor Targeting Antibodies: Distinct Innate and Adaptive Immune Sensing
Yang-Xin Fu, M.D., Ph.D., Professor of Pathology, Mary Nell and Ralph B. Rogers Professorship in Immunology, UT Southwestern
Innate and Adaptive Integrin-targeted Combination Immunotherapy
Jennifer R. Cochran, Ph.D., Co-Founder and Director, Nodus Therapeutics
NK Cell Engagement with Bispecific Antibodies
Ann Cheung, Ph.D., Director of Biology, Dragonfly Therapeutics
Anti-chaperone Antibodies in Cancer Therapy
Amy S. Lee, Ph.D., Associate Director for Basic Research, USC Norris Comprehensive Norris Cancer Center and Professor of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California
NOVEL THERAPEUTIC INDICATIONS FOR ANTIBODIES
Session Chair: James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development
Therapeutic Antibodies that Silence B Cells by Emulating Peripheral Immune Tolerance
John Cambier Ph.D., Distinguished Professor and Chair, Department of Immunology and Microbiology, University of Colorado SOM
Antibody Approaches to T1D
William Ridgway, Professor, University of Cincinnati
Action of Bispecific Anti-FGFR1/βKlotho Antibody in Obese Mice and Humans
Junichiro Sonoda, Ph.D., Senior Scientist, Cancer Immunology, Genentech
INNOVATING ANTIBODY THERAPEUTICS
Session Chair: Paul Parren, Ph.D., Senior Vice President and Scientific Director, Genmab, The Netherlands
Evolution of Antibodies of Different Germline Gene Origins Proceed through Different Paths
Mats Ohlin, Ph.D., Professor, Department of Immunotechnology & SciLifeLab, Lund University, Sweden
DNA-based Antibody Therapy via Antibody Gene Transfer
Kevin Hollevoet, Ph.D., Group Leader and Postdoc, Therapeutic and Diagnostic Antibodies, University of Leuven, Belgium
Structural Determinants for Modulating Antibody-Fc Receptor Interactions for Half-Life Enhancement and Effector Functions
Karthik Viswanathan, Ph.D., Director, Research, Visterra, Inc.